Cytosorbents

Update in progress

CTSO (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

Cytosorbents Corporation develops and commercializes blood purification devices. Its flagship CytoSorb cartridge removes inflammatory mediators, cytokines, bilirubin, myoglobin, and other toxins in critical illness, liver failure, trauma, and cardiac surgery. The company also develops DrugSorb-ATR to reduce perioperative bleeding, ECOS-300CY for ex vivo organ perfusion, VetResQ for veterinary care, and related purification platforms.

Company score

Sentiment: 0.18; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.12; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive